ARCHER 1050: first-line dacomitinib vs gefitinib for advanced NSCLC in patients with EGFR activating mutation(s)

Background: Dacomitinib (D) is an orally available, irreversible, small-molecule inhibitor of EGFR (HER1), HER2, and HER4. It has shown activity in preclinical studies on EGFR mutant cell lines, including those resistant to gefitinib (G). In a phase II trial of non-small-cell lung cancer (NSCLC) patients (pts) who received 1st-line D, 76% of 45 pts with confirmed EGFR exon 19 or 21 activating mutations (m) experienced a partial response (PR)....